Galapagos NV: Galapagos to showcase CAR-T point-of-care manu

All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1

Related Keywords

Mechelen , Region Flamande , Belgium , Zeiten , Mecklenburg Vorpommern , Germany , Japan , Daniel Estban , Sergi Betriu , Jeevan Shetty , Marieke Vermeersch , Sandra Cauwenberghs , Nuria Martinez Cibrian , Van Gijsel , Julio Delgado , Christian Jacques , Mercedes Montoro , Stefan Klotter , Valentin Ortiz Maldonado , Leticia Alserawan , Margotj Pont , Head Of Clinical Development Oncology At Galapagos , Exchange Commission , European Hematology Association , Twitter , Objective Response Rate , Clinical Development Oncology , Clinical Results , Maike Spoon , Bayesian Optimal Interval , Cancer Journal , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Galapagos , Showcase , Joint , Mare , Manufacturing , Nitial , Hase , Data , Cvd19 , Candidate , Lpg5201 , 023 , Congress ,